Nuveen’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Nuveen’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-13,719	Closed	-$203K	–	3482
2024 Q1	$203K	Hold	13,719	–	–	﹤0.01%	3183
2023 Q4	$184K	Hold	13,719	–	–	﹤0.01%	3227
2023 Q3	$169K	Hold	13,719	–	–	﹤0.01%	3065
2023 Q2	$169K	Buy	+13,719	New	+$172K	﹤0.01%	3117
2019 Q3	–	Sell	-602,214	Closed	-$2.87M	–	3293
2019 Q2	$2.87M	Buy	+602,214	New	+$2.85M	﹤0.01%	2259

Other funds holding MACK

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return

JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Nuveen's MACK Position: Q2 2024 in Review

Nuveen sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 13,719 shares — an estimated $203K sold.

Nuveen first reported a position in MACK in Q2 2019 and held it in 5 quarters. The position peaked at $2.87M in Q2 2019. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

Nuveen reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
Nuveen sold 13,719 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $203K.
Nuveen first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2019 and held it in 5 quarters.
Nuveen's Merrimack Pharmaceuticals, Inc. position peaked at $2.87M in Q2 2019.
12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Nuveen's 13F filing for Q2 2024, filed 9 Aug 2024.